

Project ECHO for Interstitial Lung Disease

Wednesday, January 15, 2025, 7am-8am EST

| | |
|------------------------|--|
| Medical Director | Robert Hallowell, MD |
| Principal Investigator | Aliaa Barakat, PhD |
| Didactic Speaker | Robert Hallowell, MD |
| Session Facilitator | Robert Hallowell, MD |
| Target Audience | The series is designed for pulmonologists, radiologists and other health providers who care for people with ILD. |

In accordance with HIPAA: All patient information will be de-identified during session.

| Time | Didactic Presentation / Case Discussion | Presenter / Facilitator |
|---------------|---|-------------------------|
| 7:00am-7:05am | Announcements and Introductions | Aliaa Barakat, PhD |
| 7:05am-7:25am | Didactic: Myositis-Associated ILD — Clinical Manifestations and Diagnosis | Robert Hallowell, MD |
| 7:25am-8:00am | Case Presentation and Discussion | Robert Hallowell, MD |
| 8am | Closing Remarks | Aliaa Barakat, PhD |



In support of improving patient care, this activity has been planned and implemented by the Pulmonary Care and Research Collaborative, Ltd. and Project ECHO®. Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ECHO Activity ID: RSS943

This session will be audio and video recorded.
Your participation confirms your consent to this recording.

Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Grace Peloquin, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

| Name | Nature of Relationship | Name of Ineligible Company |
|----------------------|--------------------------------------|---|
| Aliaa Barakat, PhD | PI - Investigator-initiated research | Genentech, Inc. |
| Katharine Black, MD | Researcher | Bayer AG |
| Fiona Gibbons, MD | Researcher | aTyr Pharma |
| Leo Ginns, MD | Researcher | Genentech, Inc., Nitto Denko, United Therapeutics |
| Robert Hallowell, MD | Researcher | Boehringer Ingelheim |
| | Consultant | Vicore Pharma, UpToDate |
| | Advisor | The Myositis Association |
| Sydney Montesi | PI - Investigator-initiated research | Boehringer Ingelheim |
| | Researcher | Pliant Therapeutics |
| | Consultant | Accendatech, DevPro Biopharma, Mediar Therapeutics, Roche |
| | Royalties or Patent Beneficiary | Wolters Kluwer |
| Peter LaCamera, MD | Researcher | Boehringer Ingelheim |
| Barry Shea, MD | Researcher | Boehringer Ingelheim, Bristol Myers Squibb, FibroGen |
| | Consultant | Pipeline Therapeutics, Radius Health |

All of the relevant financial relationships listed for these individuals have been mitigated.

ECHO Activity ID: RSS943

This session will be audio and video recorded.
Your participation confirms your consent to this recording.